Egle Therapeutics Receives €9.3 Million in State Funding Under the “Innovations in Biotherapies and Bioproduction” Call for Projects from France 2030
Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, today announced that it has secured €9.3 million in state funding under the “Innovations in Biotherapies and Bioproduction” call for projects from the France 2030 plan, managed on behalf of the French government by Bpifrance.
Founded in 2020 as a spin-off from Institut Curie, Egle Therapeutics is a clinical-stage biotechnology company specializing in immunomodulation, with the ambition to develop novel approaches to the modulation of Treg activity for the treatment of cancer and autoimmune diseases.
Egle Therapeutics has developed a proprietary translational platform to identify novel tumor-infiltrating Treg targets, with the aim of developing antibody-based candidate drugs to disable Treg function and restore an effective antitumor immune response.
In June 2020, Egle Therapeutics entered a strategic partnership with Takeda Pharmaceuticals, establishing a three-year research collaboration with an option agreement. Since its inception, the company has successfully raised nearly €56 million through equity financing and non-dilutive public funding, including the i-Lab Innovation Competition and DeepTech Development Grant.
During its Series A financing round in October 2021, the company raised €47 million, attracting renowned investors, including EQT Life Sciences, Bpifrance (INNOBIO 2 and Innovation 1), Fund Plus, Bioqube Factory Fund, T1D Fund, and Takeda Ventures.
In 2024, Egle Therapeutics achieved key milestones, including the launch of its Phase I/II clinical trial for EGL-001, the appointment of Michel Detheux as Chairman, and the appointment of Christophe Quéva as Chief Executive Officer.
“We are honored to receive this funding from the French government through France 2030. This recognition and immense support will help Egle Therapeutics advance its research and development programs in regulatory T cell modulation. The funding granted under the ‘Innovations in Biotherapies and Bioproduction’ call for projects will enable us to accelerate the development of EGL-001, our lead immuno-oncology therapeutic candidate. EGL-001 is currently being evaluated in a Phase I/II clinical trial in France and Spain.”
Christophe Quéva, CEO of Egle Therapeutics
About Egle Therapeutics
Egle Therapeutics is a biotechnology company specializing in the development of immunotherapies targeting regulatory T cells. Through its proprietary discovery platform, Egle identifies novel Treg-specific targets and develops innovative Treg-targeting therapeutic candidates for the treatment of cancer and autoimmune diseases.
Egle Therapeutics’ lead immuno-oncology candidate, EGL-001, is currently being evaluated in a Phase I/II clinical trial. In autoimmunity, the company has completed the regulatory studies and manufacturing for a CTA filing for EGL-003 and is preparing to launch a clinical trial in 2025.
For more information www.egle-tx.com
About France 2030
✔ A dual ambition: France 2030 aims to transform key economic sectors (such as healthcare, energy, automotive, aerospace, and space industries) through technological innovation while positioning France not just as a participant but as a global leader in tomorrow’s world. From fundamental research to idea generation, product development, and industrialization, France 2030 supports the entire innovation lifecycle.
✔ Unprecedented scale: France 2030 will invest €54 billion to help French companies, universities, and research institutions navigate ecological and economic transitions, ensuring they remain competitive and emerge as leaders in strategic industries. France 2030 commits to allocating 50% of its funding to decarbonization and 50% to emerging innovators, while adhering to sustainable investment principles (Do No Significant Harm).
✔ Collaborative implementation: Designed and deployed in consultation with economic, academic, local, and European stakeholders, France 2030 determines its strategic priorities through an open, competitive, and selective project application process. Selected projects receive state support to drive innovation and industrial growth.
✔ Led by the General Secretariat for Investment, on behalf of the Prime Minister, France 2030 is implemented by ADEME (Agency for Ecological Transition), ANR (National Research Agency), Bpifrance, and Banque des Territoires.
For more information: france2030.gouv.fr | @SGPI_avenir
About the Call for Projects “Innovations in Biotherapies and Bioproduction”
The call for projects “Innovations in Biotherapies and Bioproduction” is a funding initiative within the France 2030 strategy, specifically under the “Biotherapies and Bioproduction of Innovative Therapies” acceleration plan. Led by the Health Innovation Agency within the Secretariat General for Investment, the program supports excellence in biotherapy research by accelerating technology transfer and ensuring a continuous pipeline of innovations from bench to bedside.
About Bpifrance
Bpifrance provides funding solutions to businesses at every stage of their development, including loans, guarantees, and equity investment. Bpifrance also supports innovation and international expansion through offers a wide range of export financing solutions.
Additionally, Bpifrance provides advisory services, networking opportunities, and business acceleration programs for startups, small- and mid-sized enterprises. With 50 regional offices, Bpifrance ensures entrepreneurs receive close and effective support to tackle their challenges.
For more information: www.bpifrance.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317147647/en/
Contacts
contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Trust in Digital Services Declines, Finds Thales18.3.2025 10:00:00 EET | Press release
Thales, today announced the findings of its 2025 Digital Trust Index – Consumer Edition, revealing a universal decline in trust for digital services compared to this time last year. Across 13 different sectors, only insurance, banking and Government saw either their trust level remain unchanged or increase very slightly. When asked which sector they trusted with their personal data, not one sector reached above 50% approval. Thales surveyed over 14,000 consumers across 14 countries about their online relationship with brands and services, their privacy expectations, and how brands can earn their trust. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318397240/en/ ©Thales This decline in trust comes as nearly one in five (19%) have been informed that their personal data has been compromised in the past year. Consequently, 82% have abandoned a brand in the past 12 months due to concerns about how their personal data was bein
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support18.3.2025 10:00:00 EET | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. Since its launch, the fund has screened over 300 projects and made several key investments into new companies across Europe driving cutting-edge innovation in biotechnology. Among the newly established companies are BioClec, focused on breakthrough therapies for Alzheimer’s disease; Forth Therapeutics, a spin-out of the University of Edinburgh, which is advancing next-generatio
ATLAS Welcomes Strengthened Commitment to Increased Shareholder Returns from SES Board18.3.2025 09:43:00 EET | Press release
ATLAS Infrastructure (“ATLAS”) is a specialist listed infrastructure investor managing funds on behalf of long-term infrastructure clients. ATLAS’s actively managed accounts currently hold in aggregate a greater than 10% voting interest and 12.5% economic interest in SES S.A (“SES” or the “Company”). ATLAS supports the decision from the SES Board of Directors (“the Board”) to further strengthen Company governance through a modernisation of the Board structure and composition. Introducing further capital markets experience into a reduced Board of 9 increases alignment of stakeholder interests. ATLAS looks forward to continuing its engagement with the Board, the Nomination Committee and other Significant Stakeholders to assist with finding the best possible candidate during the upcoming selection process. Further, ATLAS welcomes the decision by the Board to endorse Shareholder Resolution 22 (“Resolution on Capital Return to Shareholders”) at the 2025 Annual General Meeting. The Board’s s
Fujirebio Europe Launches the INNO-LiPA® HCV 2.0 Genotyping Assay, an Efficient Aid to Personalized HCV Therapy18.3.2025 08:00:00 EET | Press release
Fujirebio Europe today announced the availability* of the INNO-LiPA HCV 2.0 Genotyping assay. The product, previously distributed by Siemens Healthcare Diagnostics Inc. under the name VERSANT HCV Genotype 2.0, is a line probe assay, for in vitro diagnostic use, designed for the qualitative detection and identification of Hepatitis C virus (HCV) genotypes 1 to 6 and subtypes a and b of genotype 1 in human serum or EDTA plasma samples. Additional subtype information is available in a majority of cases. “At Fujirebio we have been pioneering molecular testing solutions since the 1990’s with our high quality LiPA platform,” says Christiaan De Wilde, CEO at Fujirebio Europe. “The historical VERSANT HCV Genotype 2.0 Assay (LiPA) served as an efficient aid to personalized HCV therapy, and we are very pleased to maintain the availability of the test, now officially a part of our INNO-LiPA product range. We would like to extend our gratitude to all INNO-LiPA customers for their continued trust.”
Protembis Announces Formation of New Scientific Advisory Board Comprised of World-Renowned Structural Heart Experts18.3.2025 08:00:00 EET | Press release
Protembis, a privately-held emerging cardiovascular medical device company, announced today the establishment of a Scientific Advisory Board (SAB) to provide objective advice and contribute to the strategic plans of the company. Specifically, the SAB will provide overarching scientific and clinical strategic guidance, advise on emerging trends and opportunities, and provide expert counsel on scientific and clinical matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317149296/en/ The SAB will be comprised of four internationally recognized interventional cardiologists, who have made significant contributions to the understanding of the role for cerebral embolic protection (CEP) in transcatheter aortic valve replacement (TAVR): Dr Martin Leon MD, Dr Anita Asgar MD, Dr Samir Kapadia MD, and Dr Nicolas van Mieghem MD. The SAB is chaired by Dr Martin Leon, Professor of Medicine at New York’s Columbia University Irving Med
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom